First-line salvage therapy after ibrutinib progression/relapse
| . | N = 25 (%)∗ . | CR . | PR . | SD . | PD . |
|---|---|---|---|---|---|
| BR and BO | 6 (24) | 4 | 0 | 0 | 2 |
| R2 | 4 (16) | 1 | 3 | 0 | 0 |
| Phosphatidylinositol-3-kinase inhibitor | 3 (12) | 0 | 1 | 2 | 0 |
| IR or IO | 3 (12) | 0 | 1 | 1 | 1 |
| Others† | 9 (36) | 1 | 2 | 4 | 2 |
| . | N = 25 (%)∗ . | CR . | PR . | SD . | PD . |
|---|---|---|---|---|---|
| BR and BO | 6 (24) | 4 | 0 | 0 | 2 |
| R2 | 4 (16) | 1 | 3 | 0 | 0 |
| Phosphatidylinositol-3-kinase inhibitor | 3 (12) | 0 | 1 | 2 | 0 |
| IR or IO | 3 (12) | 0 | 1 | 1 | 1 |
| Others† | 9 (36) | 1 | 2 | 4 | 2 |
BO, bendamustine and obinutuzumab; BR, bendamustine and rituximab; IO, ibrutinib and obinutuzumab; IR, ibrutinib and rituximab; R2, rituximab and lenalidomide (revlimid).
Among the 43 patients who progressed/relapsed after ibrutinib, only 25 received subsequent therapy.
Others: 5 included alkylator-based (nonbendamustine) therapies, 1 platinum-based, 2 anti-CD20 monoclonal antibodies, and 1 BCL-2 inhibitor.